home / stock / phvs / phvs articles
ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 recep...
ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 recep...
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-recep...
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s sessi...
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-rece...
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-rece...
News, Short Squeeze, Breakout and More Instantly...
2024-07-03 09:30:09 ET Oppenheimer analyst issues OUTPERFORM recommendation for PHVS on July 3, 2024 07:36AM ET. The previous analyst recommendation was Outperform. PHVS was trading at $16.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-13 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasd...